Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Yaletown Bros Ventures Ltd. | BRSH Bruush Oral Care Inc. Common Stock | 13D/A | 42.6% | Jul 5, 2024 | 2y |
| Wavetech Helium, Inc. | BSIN Big Sky Industrial Inc. | 13G | 9.3% | Jun 26, 2024 | 2y |
| Griffith Curtis C | SPFI South Plains Financial, Inc. | 13G/A | 11.56% | Mar 12, 2024 | 2y |
| Blue Star Exploration Company | CRK Comstock Resources Inc | 13D/A | 69.4% | Aug 15, 2024 | 2y |
| Mink Brook Asset Management LLC | ACU Acme United Corp | 13G | 5.54% | Aug 15, 2024 | 2y |
| GAMCO INVESTORS, INC. ET AL | INVX Innovex International, Inc. | 13D/A | 6.55% | Aug 15, 2024 | 2y |
| PERCEPTIVE ADVISORS LLC | LYRA Lyra Therapeutics, Inc. | 13D/A | 19.5% | Aug 14, 2024 | 2y |
| Michael A. Davis (“Davis”) | CYAN Cyanotech Corp | 13D/A | 21.7% | Aug 14, 2024 | 2y |
| GAMCO INVESTORS, INC. ET AL | BELFA Bel Fuse Inc | 13D/A | 9% | Aug 14, 2024 | 2y |
| Joe Thomas | DTCX Datacentrex, Inc. | 13G/A | 9.84% | Aug 13, 2024 | 2y |
| GIC Private Ltd | IQV Iqvia Holdings Inc. | 13G | 5.01% | Aug 13, 2024 | 2y |
| Abdiel Qualified Master Fund, LP | APPN Appian Corp | 13D/A | 22.8% | Aug 13, 2024 | 2y |
| ORBIMED ADVISORS LLC | SCPH scPharmaceuticals Inc. Common Stock | 13D/A | 12.1% | Aug 13, 2024 | 2y |
| Pacific Investment Management Company LLC | QMCO Quantum Corp | 13D/A | 21.76% | Aug 13, 2024 | 2y |
| ORBIMED ADVISORS LLC | APLM Apollomics Inc. | 13D/A | 0.05% | Aug 13, 2024 | 2y |
| Karpus Management, Inc. | NEA Nuveen AMT-Free Quality Municipal Income Fund | 13D/A | 7.4% | Aug 12, 2024 | 2y |
| Engaged Capital LLC | PTLO Portillo's Inc. | 13D | 9.9% | Aug 8, 2024 | 2y |
| S.H.N. Financial Investments Ltd. | XPON Expion Energy, Inc. | 13G | 9.9% | Aug 7, 2024 | 2y |
| L1 Capital Global Opportunities Master Fund, Ltd. | XPON Expion Energy, Inc. | 13G | 9.9% | Aug 7, 2024 | 2y |
| Stonepine Capital Management, LLC | TENX Tenax Therapeutics, Inc. | 13G | 9.99% | Aug 6, 2024 | 2y |
| GREAT POINT PARTNERS LLC | ELEV Elevation Oncology, Inc. Common stock | 13G | 6.56% | Aug 6, 2024 | 2y |
| Mudrick Capital Management, L.P. | MARK Remark Holdings, Inc. | 13G | 9.99% | Aug 5, 2024 | 2y |
| WealthTrust Axiom LLC | EPM Evolution Petroleum Corp | 13G | 5.04% | Jul 10, 2024 | 2y |
| Xin Rong Gan | CD Chaince Digital Holdings Inc. | 13D/A | 7.6% | May 23, 2024 | 2y |
| Hailei Zhang | CD Chaince Digital Holdings Inc. | 13G/A | 3.7% | May 11, 2024 | 2y |
| Hanqi Li | CD Chaince Digital Holdings Inc. | 13D/A | 8.6% | May 1, 2024 | 2y |
| Hong Mei Zhou | CD Chaince Digital Holdings Inc. | 13D/A | 7.6% | Apr 30, 2024 | 2y |
| JACOB SAFIER | TTOO T2 Biosystems, Inc | 13G/A | 4.3% | Apr 12, 2024 | 2y |
| Safier Jacob | TTOO T2 Biosystems, Inc | 13G/A | 4.3% | Apr 12, 2024 | 2y |
| TIGER GLOBAL MANAGEMENT LLC | OKLO Oklo Inc. | 13G/A | 2.5% | Aug 14, 2024 | 2y |
| GAMCO INVESTORS, INC. ET AL | INVX Innovex International, Inc. | 13D/A | 6.55% | Aug 14, 2024 | 2y |
| BML Investment Partners, L.P. | ANTX AN2 Therapeutics, Inc. | 13G/A | 19.3% | Aug 14, 2024 | 2y |
| BML Investment Partners, L.P. | TLIS Talis Biomedical Corporation Common Stock | 13G/A | 11.2% | Aug 14, 2024 | 2y |
| EW Healthcare Partners, L.P. | VERO Venus Concept Inc. | 13D/A | 45.8% | Aug 13, 2024 | 2y |
| Edward Smolyansky | LWAY Lifeway Foods, Inc. | 13D/A | 21.5% | Aug 13, 2024 | 2y |
| Saba Capital Management, L.P. | IIF Morgan Stanley India Investment Fund, Inc. | 13D | 5.12% | Aug 13, 2024 | 2y |
| Riot Platforms, Inc. | KEEL Keel Infrastructure Corp. | 13D/A | 18.9% | Aug 13, 2024 | 2y |
| Shoshana Shendelman | APLT Applied Therapeutics, Inc. Common Stock | 13D/A | 6.6% | Aug 12, 2024 | 2y |
| James Lim | STEP StepStone Group Inc. | 13D/A | 8.3% | Aug 12, 2024 | 2y |
| WP Triton Co-Invest, L.P. | VSAT Viasat Inc | 13D/A | 6.57% | Aug 12, 2024 | 2y |
| Jeffrey Allen Morris | PVCT Provectus Biopharmaceuticals, Inc. | 13G | 11.3% | Aug 12, 2024 | 2y |
| Archon Capital Management LLC | STIM Neuronetics, Inc. | 13G/A | 3% | Aug 12, 2024 | 2y |
| 325 CAPITAL LLC | APEI American Public Education Inc | 13D/A | 10.8% | Aug 12, 2024 | 2y |
| Growth Equity Opportunities 17, LLC | SVRA Savara Inc | 13D/A | 14.9% | Aug 12, 2024 | 2y |
| GKCC, LLC | ELTX Elicio Therapeutics, Inc. | 13D/A | 38.7% | Aug 12, 2024 | 2y |
| MFN Partners, LP | RXO RXO, Inc. | 13G/A | 19.9% | Aug 12, 2024 | 2y |
| ONTARIO TEACHERS PENSION PLAN BOARD | VSAT Viasat Inc | 13D/A | 6.69% | Aug 12, 2024 | 2y |
| PERCEPTIVE ADVISORS LLC | MGTX MeiraGTx Holdings plc | 13D/A | 16.4% | Aug 12, 2024 | 2y |
| Mount Grey Partners LP | CLST Catalyst Bancorp, Inc. | 13G/A | 0% | Aug 12, 2024 | 2y |
| Todd Deutsch | AIM AIM ImmunoTech Inc. | 13D/A | 3% | Aug 12, 2024 | 2y |